Custom Antibody Services Market
Custom antibodies are essential to personalized therapies, as they can be designed to target specific molecular markers that are unique to an individual patient’s disease. As an award-winning custom antibody supplier with over 14,000 monoclonal and 110,000 polyclonal antibodies generated to date, GenScript offers comprehensive antibody development and production services. GenScript houses all rodents and rabbits for antibody generation in an OLAW and AAALAC internationally accredited animal facility. The increasing prevalence of chronic diseases and rising approvals of biosimilars are noteworthy factors contributing to the growing custom antibody services market size. However, the high costs and complexities associated with antibody production using transgenic animals hinder market growth. Moreover, technological advancements using recombinant antibodies are expected to bring new custom antibody services market trends in the coming years.
Rising Prevalence of Chronic Diseases Fuels Custom Antibody Services Market Growth
The growing aging population, changing social behavior, and increasing adoption of a sedentary lifestyle by people, along with accelerating urbanization, boost the prevalence of obesity and various chronic diseases. Also, twin studies have established that genes can cause chronic conditions such as cardiovascular disease (CVDs), diabetes, obesity, Alzheimer’s disease (AD), and depression. As per the National Council on Aging, Inc., 80% of adults aged 65 and above suffer from at least one chronic condition, while 68% have two or more. As per the Centers for Disease Control and Prevention, almost 6 in 10 people in the US suffered from at least one chronic disease in 2020, and 4 in 10 people had two or more chronic conditions.
Cardiovascular diseases such as angina pectoris, atherosclerosis, and acute myocardial infarction, caused due to hectic lifestyles, are significant causes of mortality across the globe. As per the data provided by the WHO, CVDs are the leading cause of death worldwide, recording ~17.9 million deaths yearly. Diabetes is a life-threatening chronic disease with no functional cure. Diabetes of all types can lead to various complications in the body and increase the risk of premature death. Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are among the foremost complications associated with diabetes. According to the International Diabetes Federation, diabetic cases in North America are anticipated to reach 62 million by 2045 from 46 million in 2017. Furthermore, 425 million people were suffering from diabetes in 2017, and the figure is expected to reach 629 million by 2045 worldwide; this is likely to boost the disease prevalence by ~35% during the forecast period.
Recognition of biosimilars and monoclonal antibodies as efficient and safe agents by patients, specialists, primary care clinicians, and other healthcare experts is propelling the demand for biosimilars. Additionally, biosimilars can enhance the quality of life for millions of patients while reducing costs for the healthcare system per year. They are efficient and cost-effective options in treating many diseases, including chronic skin conditions and bowel diseases, such as irritable bowel syndrome, Crohn’s disease, psoriasis, and colitis; diabetes; cancer; autoimmune disease; kidney conditions; and arthritis. As the prevalence of chronic diseases is growing at a high rate, the demand for custom antibodies to treat life-threatening illnesses has progressed rapidly over the past few years, thereby fueling the custom antibody services market growth.
Custom Antibody Services Market: Competitive Landscape and Key Developments
Thermo Fisher Scientific Inc.; Sino Biological Inc.; GenScript Biotech Corporation; Biochain Incorporated; R&D Systems, Inc.; Kaneka Eurogentec S.A.; Fortis Life Sciences; Precision Antibody; Biocytogen Pharmaceuticals Beijing Co Ltd; Abgenex; Creative Biolabs Inc; Agilent Technologies Inc.; Bioklone.; and Scantibodies Laboratory, Inc. are a few key companies operating in the market. These companies focus on product innovation strategies to meet evolving customer demands, along with maintaining their brand name in the custom antibody services market.
As per company press releases, a few recent developments initiated in the custom antibody services market report are mentioned below:
- In March 2024, Sino Biological, Inc. entered into a services partnership with Toronto, Canada-based Rapid Novor, Inc. Under the terms of the agreement, Sino Biological sells Rapid Novor’s proprietary de novo REmAb monoclonal antibody (mAb) sequencing service in combination with its custom mAb development and production services. Geographic areas covered under the partnership include China, Singapore, Thailand, Malaysia, Indonesia, Vietnam, the Philippines, Japan, and South Korea.
- In October 2022, Fortis Life Sciences, a provider of high-quality reagents and custom services for discovery, development, and manufacturing, opened an office in Seoul, South Korea, to expand its international presence. The strategic milestone is a significant step in enhancing Fortis’ commitment to serving the Asian market and increasing its personal connection with the customer base.
- In June 2022, Precision Antibody entered into an exclusive license agreement with trans-chromosomic (Tc) mice carrying mini-chromosomes with megabase-sized human immunoglobulin (Ig) loci. Precision Antibody has developed a proprietary method to develop a strong immune response against therapeutic targets in three weeks, enabling the development of a fully human therapeutic antibody in 60 days. Through extensive, high-throughput DNA sequencing, it has been observed that the human Ig repertoire is well reconstructed in TC-mAb mice. TC-mAb mice possess more subsets of antigen-specific plasmablast and plasma cells than wild-type mice, thus enabling efficient hybridoma production.
- In March 2022, Fortis Life Sciences acquired Abcore, a California, USA-based antibody discovery platform specializing in single-domain antibody technology. With the addition of Abcore, Fortis extends its capabilities into the antibody discovery market, serving biopharma customers who are developing antibody- and VHH-based therapeutics.
